219 results on '"Loges S"'
Search Results
2. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
3. Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
4. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
5. Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo
6. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
7. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
8. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
9. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
10. Small molecule Axl inhibitor BGB324 inhibits primary chronic phase chronic myeloid leukaemia (CML) cell function and viability: 289
11. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
12. Development of targeted angiogenic medicine
13. Response to treatment of uncommon EGFR mutations : a retrospective analysis from the German National Network Genomic Medicine Lung Cancer (nNGM)
14. Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
15. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo
16. Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
17. Anti-angiogenesis in oncology: Mechanisms of action and resistance: V169
18. In vitro differentiation of AC133-positive precursor cells into haematopoietic and endothelial cells at the single-cell level: Evidence for the postnatal haemangioblast: 493
19. Use of AC133-derived endothelial progenitor cells for coating of intracoronary stents: 83
20. INCREASED INCIDENCE OF ANTI-LKM IN A CONSECUTIVE SAMPLE OF HCV PATIENTS FROM CENTRAL GREECE: A PRELIMINARY STUDY
21. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
22. PF259 THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL-INHIBITOR AND LOW-DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
23. PS999 SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
24. HEPATIC AUTOANTIGENS IN THE AUTOIMMUNE POLYGLANDULAR SYNDROME TYPE 1 AND AUTOIMMUNE HEPATITIS TYPE 2
25. LKM AUTOANTIBODIES IN AUTOIMMUNE HEPATITIS, APS1 AND CHRONIC HEPATITIS C: QUANTIFICATION OF ANTI-CYP2D6 AUTOANTIBODIES WITH35 S-LABELED RECOMBINANT PROTEIN AND COMPARISON OF TARGET PROTEINS
26. RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
27. The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients
28. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
29. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
30. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
31. Nature
32. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
33. Regulating the activity of p38α/β as a potential therapy against childhood acute lymphoblastic leukemia
34. Anti-neutrophilen zytoplasmatische Antikörper (ANCA) in der Galle korrelieren mit dem Schweregrad des cholangiographischen Befundes bei Patienten mit PSC
35. [Heterogeneity of antimicrosomal autoantibodies in chronic hepatitis C virus infection and delta hepatitis]
36. Autoimmunty in patients with chronic hepatitis type D and C
37. Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
38. Analysis of four human PlGF isoforms and of VEGFR-1 in esophageal carcinoma.
39. Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates
40. 'Autoimmune Manifestations in patients with chronic hepatitis and Human Immunodeficiency (HIV) infection
41. BCR/ABL status of blood outgrowth endothelial cells from CML patients
42. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C virus (HCV) infection
43. The tyrosine kinase src plays a crucial role in leukemic cell proliferation in AML
44. Comparison of combination treatment with endostatin, soluble neuropilin-1 and thrombospondin-2 to single inhibitors in antiangiogenic therapy of renal cell carcinoma
45. Detection of circulating lymphendothelial cells in patients with solid tumors
46. Determination of microvessel density by real-time PCR in esophageal cancer: Correlation with histological methods, angiogenic growth factor expression and lymph node metastasis
47. LKM autoantibodies in autoimmune hepatitis, APS1 and chronic hepatitis C: quantification of anti-CYP2D6 autoantibodies with 35S-labeled recombinant protein and comparison of target proteins
48. Definition of a novel CYP2D6 epitope in autoimmune hepatitis type 2 and in chronic hepatitis C
49. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
50. A Major CYP2D6 Autoepitope in Autoimmune Hepatitis Type 2 and Chronic Hepatitis C is a Three-dimensional Structure Homologous to Other Cytochrome P450 Autoantigens.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.